In order to improve cutting-edge knowledge on Rare Hematological Diseases (RHD), ERN-EuroBloodNet has identified across Europe the healthcare areas including highly specialized procedures requiring preceptorship for the acquisition of medical expertise. Two first interventional healthcare area identified were: 1) Inherited and acquired bone marrow failures (Aplastic Anaemia and Paroxysmal Nocturnal Hemoglobinuria) in adult and pediatric patients and 2) Sickle cell disorders in adult and pediatric patients.
The First interventional healthcare area approached was: Inherited and acquired bone marrow failures including Aplastic Anaemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) in adult and pediatric patients.
ERN-EuroBloodNet endorsed three preceptorships held in ERN-EuroBloodNet highly specialized centers for AA and PNH with the objective to provide applicants with the fundamental tools for a correct diagnostic and treatment approach to bone marrow failures, including AA and PNH in children, adolescents and adult patients.
The highly specialized centers hosting the preceptorships are ERN-EuroBloodNet members that represent the excellence in RHD field at International level.This call is closed, more information on other disease programs such as Sickle Cell Disease will come soon.
From 13/01/2020 to 16/01/2020 (4 days)
Host Center: AP-HP, Hôpital Saint-Louis, Paris, France
Coordinated by: Prof Regis Peffault de la Tour
From 03/02/2020 to 5/02/2020 (3 days)
Host Center: Federico II University of Naples, Italy
Coordinated by: Prof. Antonio Risitano
From 17/02/2020 to 20/02/2020 (4 days)
Coordinated by: Dr. Carlo Dufour
The three EuroBloodNet Preceptorships have been successfully accredited by EBAH (European Board for Accreditation in Hematology)
The Preceptorship program for AA and PNH is closed with a total of 13 Participants from 8 Member States attending to:
Congratulations to all!
EuroBloodNet Association is in charge to cover the costs for travel and accommodation of participants. EuroBloodNet Association will also provide for costs of daily stay and it will support logistic and arrangements for the educational material and it will be in charge of costs of logistic and arrangement site organization.
Preceptorship on AA and PNH are partially supported by EuroBloodNet Association through a Grant received from Alexion Pharma France.
The second interventional healthcare area identified is Sickle Cell Disease. The organization of this preceptorship has been delayed because of the COVID-19 pandemia. Further information will be available soon.
Are you willing to benefit for EuroBloodNet Preceptorship programs? Stay tuned! More information on other disease programs will come soon!